This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / REGENXBIO Class Action Lawsuit Over RGX-111
Business class action lawsuit

REGENXBIO Class Action Lawsuit Over RGX-111

Analysis based on 13 articles · First reported Feb 17, 2026 · Last updated Mar 09, 2026

Sentiment
-40
Attention
2
Articles
13
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against REGENXBIO and the United States===Food and Drug Administration's clinical hold on RGX-111 have negatively impacted REGENXBIO's stock price. This event highlights the risks associated with clinical-stage biotechnology companies and their product development.

Biotechnology Legal Services
Event Summary

The Portnoy Law Firm is advising investors of REGENXBIO, Inc. of a class action lawsuit. The lawsuit alleges that REGENXBIO disseminated false and misleading statements regarding the efficacy and safety of its RGX-111 trial study. This follows an announcement on January 28, 2026, that the U.S. Food & Drug Administration placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a participant. Following this news, REGENXBIO's stock price fell by nearly 18%. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, have until April 14, 2026, to file a lead plaintiff motion.

Key Actions
95 United States===Food and Drug Administration placed clinical hold on gene therapy REGENXBIO
90 Portnoy Law Firm advises investors of class action lawsuit REGENXBIO
85 REGENXBIO stock price fell
Entities Involved
stock
REGENXBIO
REGENXBIO is facing a class action lawsuit due to allegedly disseminating false and misleading statements regarding the efficacy and safety of its RGX-111 trial study. The U.S. Food & Drug Administration placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a participant, causing REGENXBIO's stock price to fall by nearly 18%.
Importance 100 Sentiment -60
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration placed a clinical hold on REGENXBIO's investigational gene therapy RGX-111, which is a key event leading to the class action lawsuit against REGENXBIO.
Importance 80 Sentiment 0
priv
Portnoy Law Firm
The Portnoy Law Firm is advising REGENXBIO investors of a class action lawsuit and is representing investors in pursuing claims against REGENXBIO. The firm is actively seeking lead plaintiffs for the lawsuit.
Importance 70 Sentiment 50
per
Lesley F. Portnoy
Lesley F. Portnoy is an attorney at the Portnoy Law Firm and is encouraging investors to contact her to discuss their legal rights regarding the REGENXBIO class action lawsuit.
Importance 30 Sentiment 40
exch
Nasdaq
REGENXBIO is listed on Nasdaq, and its stock price fell nearly 18% following the news of the clinical hold on RGX-111.
Importance 10 Sentiment 0
Relationships
Lesley F. Portnoy related ↔ Portnoy Law Firm
REGENXBIO related ↔ United States===Food and Drug Administration
REGENXBIO related ↔ Portnoy Law Firm
Portnoy Law Firm related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.